Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

Inclusion criteria:

• Male or non-pregnant, non-lactating female patients at least 18 years of age

• Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 monthswith moderate to severe PsA who must have at Baseline ≥3 tender joints out of 78 and ≥3 swollen out of 76 (dactylitis of a digit counts as one joint each)

• Rheumatoid factor and anti-CCP antibodies negative

• Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥2cmdiameter or nail changes consistent with psoriasis or documented history o plaquepsoriasis

Exclusion criteria:

• Chest X-ray with evidence of ongoing infectious or malignant process

• Subjects who have previously been treated with more than 3 different TNFα inhibitors

• Subjects taking high potency opioid analgesics

• Subjects who have ever received biologic immunomodulating agents except for thosetargeting TNFα Other protocol-defined inclusion/exclusion criteria may apply